<DOC>
	<DOCNO>NCT01048827</DOCNO>
	<brief_summary>Busulfan etoposide use preparative therapy autoSCT ( stem cell transplant ) adult acute myeloid leukemia ( AML ) UCSF past 10 year . Over period together collaborative transplant center , 200 patient receive treatment . By intent-to-treat analysis , median follow-up 7.0 year , 5-year DFS 55 % . The current protocol utilize combination IV Busulfan ( BU ) etoposide . The busulfan dose escalate amongst 3 target dose level . All target dose level represent high busulfan dose standard myeloablative dosing , low dose approximately 14 % high standard . Busulfan level monitor first , fourth twelfth dos . Dose adjustment make `` real time '' base AUC level determine first fourth dos . This strategy busulfan monitor dose adjustment improve therapeutic widow BU previous clinical trial . The current protocol utilize combination intravenous busulfan etoposide . The busulfan dose escalate amongst 3 target dose level ( area curve ( AUC ) level time 6 hour 1250 uMol*min , 1400 uMol*min 1550 uMol*min ) . All target dose level represent high busulfan dose standard myeloablative dosing low dose ( 1250 uMol*min ) approximately 14 % high standard . In absence dose-limiting toxicity , cohorts 4-6 patient treat dose level 10 additional patient treat maximum tolerate dose ( MTD ) confirm safety . The busulfan dose begin 1 mg/kg base historical plasma level obtain patient receive BU start dose 0.8 mg/kg UCSF Medical Center . The high dose level propose study exceed report toxic level busulfan alloSCT set . Patients follow closely toxicity strict stopping rule include . Eligibility criterion exclude patient prior history hepatotoxicity viral hepatitis . Potential hepatotoxic agent allow prior busulfan dose period . In addition , patient experience hepatotoxicty pre-transplant mobilization therapy may exclude receive dose-escalated busulfan therapy . Every attempt make prevent avoid hepatotoxicity .</brief_summary>
	<brief_title>Targeted , Dose-Escalation Busulfan-Etoposide Prep Regimen</brief_title>
	<detailed_description>TREATMENT : STEP 1 - CONSOLIDATION CHEMOTHERAPY - Etoposide 10 mg/kg IV continuous infusion 24 hr 4 day ( total course dose 40 mg/kg ) . Dose base correct weight , calculate follow : Ideal + 25 % difference actual ideal weight . If actual less ideal weight use actual weight . Etoposide infusion mix normal saline concentration 0.4-0.5 mg/ml . The infusion volume approximately 1.39 ml/kg/hour round near 500-1000 ml infused central venous catheter . - Cytarabine ( ara-C ) 2,000 mg/m2 IV 2 h q 12 h x 8 dos Days 1-4 . Cytarabine dosage base correct weight , calculate follow : Ideal weight + 25 % difference actual ideal weight . If actual weight less ideal weight , use actual weight.Begin concurrent etoposide infusion . Cytarabine dose mixed 250 ml D5W . To prevent neurotoxicity high-dose cytarabine ( HDAC ) , cytarabine dos adjust accord renal function . The dose cytarabine reduce 1000 mg/m2/dose creatinine 1.5-1.9 mg/dL increase baseline creatinine start cytarabine 0.6-1.1 mg/dL ( example : baseline creatinine 0.8 mg/dL increase 1.4 mg/dL ( difference 0.6 mg/dL ) ) , decrease cytarabine 1000 mg/m2/dose.The dose cytarabine reduce 100 mg/m2/dose creatinine &gt; 2.0 mg/dL increase baseline &gt; 1.2 mg/dL.Cytarabine discontinue immediately clinical evidence cerebellar neurotoxicity ( dysarthria , dysmetria , gait disturbance ) . Supportive Care Measures : - G-CSF 5 mcg/kg ( actual body weight ) SQ daily begin day 14 . The dose increase 10 mcg/kg WBC &gt; 1000/uL achieve . G-CSF 10 mcg/kg continue peripheral blood stem cell collection complete . All G-CSF dos round convenient dose base vial size 300 480mcg . - Fluoromethalone 0.1 % ophthalmic solution ( equivalent medication ) 2 drop qid eye Days 1-6 . - Voriconazole 200 mg PO Q12 hour begin day completion chemotherapy ( Day +6 ) . Equivalent anti-fungal prophylaxis itraconazole , posaconazole Liposomal-based amphotericin ( 1mg/kg ) may use . - Patients hospitalized private room possible . - Strict low bacteria diet used ANC &lt; 500 cells/uL . - Recommended mouth care : . Salt soda swish tid - Transfusions : Institution standard follow blood product support . In lieu standard , pack RBCes give maintain hemoglobin &gt; 8.5 gm/dl hematocrit &gt; 25 % . Platelet transfuse keep platelet count &gt; 10-20 x 109/l . Blood filter irradiate ( 3000 cGy ) . CMV seronegative patient receive CMV-seronegative blood product available . PERIPHERAL BLOOD STEM CELL ( PBSC ) COLLECTION - Begin collection total white blood count exceed 10,000/µl appropriate base peripheral CD34 cell count ( institutional standard ) - Aim total 1-4 collection standard target CD34 cell dose &gt; 5 x 10 x 106/kg optimal target CD34 cell dose &gt; 10 x 106/kg . The minimum CD34 cell dose &gt; 3 x 106/kg . Collections continue 10 x 106/kg CD34 ( + ) cell dose achieve unless clinically feasible . - Stem Cell Collection : Process 18-20 L whole blood 3-4 hour accord institutional standard . - PBSC Processing : The buffy coat concentrate centrifugation Beckman centrifuge . Cells suspend Normasol medium 5 % autologous plasma 10 % DMSO final cell concentration 2.5 x 108/ml . Seventy ml aliquot place polyolefin bag freeze control rate freezer . Bags label stored liquid phase liquid nitrogen freezer . Institutional standard PBSC processing follow . - Four 2 ml aliquot PBSC freeze liquid nitrogen future analysis . TREATMENT : STEP 2 - AUTOLOGOUS STEM CELL TRANSPLANT - Mandatory Recovery Period : The patient may begin preparative therapy stem cell transplant follow minimum four week `` out-of-hospital '' time since discharge consolidation/mobilization chemotherapy . - Dose-Adjusted Busulfan 1 . Busulfan dose calculate use correct weight equal ideal weight + 25 % difference actual ideal weight . If actual weight less ideal weight use actual weight . 2 . The initial dose busulfan ( Dose cohort # 1 = 1 mg/kg , Dose cohort # 2 = 1.2 mg/kg , Dose cohort # 3 = 1.4 ) give single intravenous dose Day -10 ( morning , 9:00AM ) . The dose administer intravenous injection 2 hour Outpatient Ambulatory Care/Infusion Center . 1 . The infusion tube prim busulfan dilute saline ensure complete administration 2 hour detail Appendix 10 . 2 . The busulfan administer well functioning central venous catheter . The busulfan infusion tube connect directly central venous catheter hub ( i.e . directly catheter ) ensure busulfan administration two hour . 3 . Busulfan level de drawn 2 , 3 , 4 6 hour start Busulfan Dose # 1 . For Doses # 4 # 12 , level draw prior infusion 2 , 3 , 4 6 hour , well function peripheral IV . ( SEE Appendix 9 busulfan sample ) - After busulfan administer Day -10 , serial serum sample obtain , patient discharge ACC infusion center . - Busulfan dose resume start day -8 give IV q6h additional 15 dos ( total 16 dos ) . Patients UCSF receive busulfan chemotherapy 11 Long Adult Inpatient Unit . Dose # 2 administer approximately 8 pm . This dose adjust base target dose level PK data result follow dose # 1 . The second dose give PK data available dose # 1 . - PK study also perform follow 4th 12th dos . The final busulfan dose-adjustment make approximately dose # 10 determine PK data . In case , dose-adjustment may delay due travel time problem reference lab . No dose-adjustment make data obtain sampling make follow 12th dose . - Dose adjustment base standard formula recommend reference laboratory . Adjustments make achieve target AUC level dose 2 16 . Dose adjustment calculate confirm two physician ( include one co-PI 's , possible ) UCSF Medical Center . Dose adjustment busulfan laboratory value also review regularly Jeanine McCune Ph D. , University Washington , Seattle , WA . Dr. McCune collaborator trial manages Busulfan pharmacokinetics laboratory Seattle . She leader field Busulfan metabolism , pharmacokinetics administration .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Before Consolidation Chemotherapy Age 1869 year Diagnosis AML CR ≤2 course induction chemotherapy . Out hospital minimum 4 week induction chemotherapy 3 week consolidation chemotherapy administer . Remission bone marrow bx w/i 2 wks begin post remission rx . One cycle postremission consolidation w/standard dose cytarabine HDAC &lt; 8 dos HDAC . Benign CSF : Lumbar puncture cell count , differential protein determine lack extramedullary leukemia require w/i 2 week post remission therapy IF CSF status unknown positive dx . No active infection No evidence prior liver disease . Creatinine &lt; 2.0 mg/dl . Cardiac ejection fraction ≥40 % . Adequate pulmonary function DLCO ≥40 % predict . No comorbid medical condition would jeopardize chance tolerate aggressive chemotherapy . ECOG 02 Signed inform consent . Eligibility Reassessed Before Autologous SCT Minimum 4 week hospital postremission rx . Continued CR document bone marrow morphology cytogenetics ( previously abnormal ) , perform within 2 wks admission autologous transplantation . Adequate marrow recovery postremission therapy demonstrate ANC ≥ 500/µl , platelet ≥ 50,000/µl stable improve hemoglobin ( transfusion independent ) . Adequate peripheral stem cell collect store ; No evidence liver dysfunction determine within 2 week transplant admission . Bilirubin must &lt; 2.0 mg/dl AST alkaline phosphatase &lt; 3x upper limit normal . Creatinine &lt; 2.0 mg/dl . No active infection need ongoing antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>autologous transplant</keyword>
</DOC>